# Beyond mobility: A prospective study on diet and metabolism in hereditary spastic paraplegia

**Authors:** Christina Erhardt, Imke T. Spatz, Hans J. Herrmann, Zacharias Kohl, Yurdagül Zopf, Heiko Gassner, Jürgen Winkler, Martin Regensburger

PMC · DOI: 10.1007/s11011-026-01815-x · Metabolic Brain Disease · 2026-03-03

## TL;DR

This study explores how diet and metabolism affect hereditary spastic paraplegia, finding that muscle mass loss and nutritional factors are linked to disease progression.

## Contribution

The study introduces a novel focus on nutritional counseling's impact on HSP progression and metabolism across specific genotypes.

## Key findings

- SPG11-associated HSP patients had significantly higher BMI compared to healthy populations.
- Disease severity in HSP correlated negatively with muscle mass, protein, and fiber intake.
- After one year, patients experienced significant loss of relative muscle mass.

## Abstract

Metabolism plays an important role in neurodegenerative diseases. Hereditary spastic paraplegias (HSP) are a heterogeneous group of rare genetic neurodegenerative disorders, commonly characterized by the clinical syndrome of progressive lower limb spasticity and mobility loss. Obesity has been linked to distinct genotypes, but the role of metabolism and nutrition in HSP remains unclear.We aimed to To evaluate metabolism and nutrition in specific HSP genotypes and to assess the impact of nutritional counseling on disease progression and body composition. In this prospective explorative pilot study, we assessed the neurological, metabolic and nutritional status of patients with HSP at baseline and one year after nutritional counseling. A total of 36 patients with genetically confirmed SPG4-, SPG7- and SPG11-associated HSP were recruited. BMI in SPG4 and SPG7 was comparable to healthy population data, whereas SPG11 showed significantly higher BMI (+ 22.9%, p < 0.05) with a considerable interindividual variability. Across all genotypes, disease severity according to the Spastic Paraplegia Rating Scale correlated negatively with leg muscle mass (ρ = -0.39, p < 0.05), protein (ρ = -0.35, p < 0.05) and fiber intake (ρ = -0.41, p < 0.05). After one year, there was a significant loss of relative muscle mass (-7.2%, p < 0.001). Progressive loss of muscle mass in HSP asks for an effective nutritional intervention combined with exercise in order to influence disease progression in HSP. The SPG11-associated obese phenotype may evolve with disease progression due to multifactorial metabolic changes, beyond reduced mobility.

The online version contains supplementary material available at 10.1007/s11011-026-01815-x.

## Linked entities

- **Genes:** SPAST (spastin) [NCBI Gene 6683], SPG7 (SPG7 matrix AAA peptidase subunit, paraplegin) [NCBI Gene 6687], SPG11 (SPG11 vesicle trafficking associated, spatacsin) [NCBI Gene 80208]
- **Diseases:** hereditary spastic paraplegia (MONDO:0019064), HSP (MONDO:0019064)

## Full-text entities

- **Genes:** POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, ALS5 [NCBI Gene 255], SPAST (spastin) [NCBI Gene 6683] {aka ADPSP, FSP2, SPG4}, SPG11 (SPG11 vesicle trafficking associated, spatacsin) [NCBI Gene 80208] {aka ALS5, CMT2X, KIAA1840}, SPG7 (SPG7 matrix AAA peptidase subunit, paraplegin) [NCBI Gene 6687] {aka CAR, CMAR, PGN, SPG5C}
- **Diseases:** SPRS (MESH:D010264), spastic paraparesis (MESH:D020336), HSP (MESH:D015419), gangliosidosis (MESH:D005733), Friedreich's ataxia (MESH:D005621), brain tumors (MESH:D001932), loss of muscle mass (MESH:C536030), movement disorders (MESH:D009069), walking disability (MESH:D013009), Obesity (MESH:D009765), inherited neurodegenerative disorders (MESH:D020271), decreased appetite (MESH:D001068), vitamin D deficiency (MESH:D014808), overweight (MESH:D050177), hyperphagia (MESH:D006963), muscle loss (MESH:D009135), peripheral motor neuropathy (MESH:D010523), lymphedema (MESH:D008209), neoplasia (MESH:D009369), diabetes (MESH:D003920), COVID-19 (MESH:D000086382), juvenile amyotrophic lateral sclerosis type 5 (MESH:C566576), Prader-Willi syndrome (MESH:D011218), prediabetic (MESH:D011236), dysphagia (MESH:D003680), ALS (MESH:D000690), metabolic syndrome (MESH:D024821), sarcopenia (MESH:D055948), muscle wasting (MESH:D009133), genetic neurodegenerative disorders (MESH:D019636), trauma (MESH:D014947), leg spasticity (MESH:D009128), mitochondrial dysfunction (MESH:D028361), arterial hypertension (MESH:D000081029), muscle (MESH:D019042), mobility loss (MESH:D014086), hypothalamic atrophy (MESH:D007027), hypothyroidism (MESH:D007037), rare (MESH:D035583)
- **Chemicals:** alcohol (MESH:D000438), T3 (MESH:D014284), vegetable oils (MESH:D010938), cholesterol (MESH:D002784), water (MESH:D014867), lipid (MESH:D008055), cholecalciferol (MESH:D002762), cortisol (MESH:D006854), Carbohydrates (MESH:D002241), Triglyceride (MESH:D014280), Vitamin D (MESH:D014807), Attract 044-602140 (-), T4 (MESH:D013974), salt (MESH:D012492), sugar (MESH:D000073893)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956933/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956933/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956933/full.md

---
Source: https://tomesphere.com/paper/PMC12956933